[{"id":"3b6e3d94-f722-44f3-897f-bf1317cea5d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672095","created_at":"2023-01-05T14:58:27.769Z","updated_at":"2025-02-25T14:09:21.750Z","phase":"Phase 1/2","brief_title":"Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer","source_id_and_acronym":"NCT05672095","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA wild-type","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/18/2025","start_date":" 04/18/2025","primary_txt":" Primary completion: 11/27/2026","primary_completion_date":" 11/27/2026","study_txt":" Completion: 11/27/2026","study_completion_date":" 11/27/2026","last_update_posted":"2025-02-18"},{"id":"9306dfb7-3366-4bae-b67b-1347cc62c160","acronym":"SALVOVAR","url":"https://clinicaltrials.gov/study/NCT06476184","created_at":"2025-02-26T14:20:08.949Z","updated_at":"2025-02-26T14:20:08.949Z","phase":"Phase 3","brief_title":"Utility of Adjusting Chemotherapy Dose \u0026 Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery","source_id_and_acronym":"NCT06476184 - SALVOVAR","lead_sponsor":"ARCAGY/ GINECO GROUP","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA wild-type • BRCA mutation","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA wild-type • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 08/05/2024","start_date":" 08/05/2024","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-11-18"},{"id":"a4f76001-f10a-4bdc-ab2f-fdaa1d20a9a2","acronym":"LUZERN","url":"https://clinicaltrials.gov/study/NCT04240106","created_at":"2021-01-18T20:37:02.911Z","updated_at":"2025-02-25T13:19:16.042Z","phase":"Phase 2","brief_title":"Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)","source_id_and_acronym":"NCT04240106 - LUZERN","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • HRD • BRCA • RAD51","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HRD • BRCA wild-type • HR positive + HER-2 negative","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • HRD • BRCA • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HRD • BRCA wild-type • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 11/17/2022","primary_completion_date":" 11/17/2022","study_txt":" Completion: 11/17/2023","study_completion_date":" 11/17/2023","last_update_posted":"2024-02-16"},{"id":"a012529c-d433-4cc1-950b-b069e61ba45c","acronym":"MIROVA","url":"https://clinicaltrials.gov/study/NCT04274426","created_at":"2021-01-18T20:45:40.588Z","updated_at":"2024-07-02T16:35:23.352Z","phase":"Phase 2","brief_title":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","source_id_and_acronym":"NCT04274426 - MIROVA","lead_sponsor":"AGO Research GmbH","biomarkers":" BRCA1 • BRCA2 • FOLR1 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA wild-type","tags":["BRCA1 • BRCA2 • FOLR1 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • doxorubicin liposomal"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-15"},{"id":"b915c927-9f08-4473-82e2-26026ef52cc1","acronym":"REFIRM","url":"https://clinicaltrials.gov/study/NCT06086665","created_at":"2023-10-17T15:12:45.504Z","updated_at":"2024-07-02T16:35:33.354Z","phase":"","brief_title":"The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer","source_id_and_acronym":"NCT06086665 - REFIRM","lead_sponsor":"Asan Medical Center","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA wild-type • BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA wild-type • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Completed","enrollment":" Enrollment 850","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2022","study_completion_date":" 10/31/2022","last_update_posted":"2023-10-17"},{"id":"8a7c54f6-440c-4908-b1b5-80217f424c46","acronym":"","url":"https://clinicaltrials.gov/study/NCT06063070","created_at":"2023-10-02T20:12:38.146Z","updated_at":"2024-07-02T16:35:35.144Z","phase":"Phase 2","brief_title":"First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer","source_id_and_acronym":"NCT06063070","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA wild-type","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • AiRuiYi (fluzoparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 10/30/2027","study_completion_date":" 10/30/2027","last_update_posted":"2023-10-02"},{"id":"eee52d84-174d-4b32-9e9a-731b67d54fb9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02482311","created_at":"2021-01-18T11:57:16.735Z","updated_at":"2024-07-02T16:35:44.114Z","phase":"Phase 1","brief_title":"Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT02482311","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA wild-type","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 01/25/2018","primary_completion_date":" 01/25/2018","study_txt":" Completion: 08/22/2019","study_completion_date":" 08/22/2019","last_update_posted":"2023-07-03"},{"id":"ef34af80-bc5d-43b8-a58e-cbcbf1d862b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02797977","created_at":"2021-01-18T13:43:39.707Z","updated_at":"2024-07-02T16:35:45.278Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects","source_id_and_acronym":"NCT02797977","lead_sponsor":"Sierra Oncology LLC - a GSK company","biomarkers":" TP53 • BRCA1 • BRCA2 • MSI • RB1 • CCNE1 • BRCA","pipe":" | ","alterations":" MSI-H/dMMR • BRCA wild-type","tags":["TP53 • BRCA1 • BRCA2 • MSI • RB1 • CCNE1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • SRA737"],"overall_status":"Completed","enrollment":" Enrollment 153","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 04/08/2020","primary_completion_date":" 04/08/2020","study_txt":" Completion: 04/08/2020","study_completion_date":" 04/08/2020","last_update_posted":"2023-06-22"},{"id":"1c1d8eb2-9176-48d0-b9e5-e8d04bca5eef","acronym":"QUADRA","url":"https://clinicaltrials.gov/study/NCT02354586","created_at":"2021-01-18T11:12:13.643Z","updated_at":"2024-07-02T16:36:03.841Z","phase":"Phase 2","brief_title":"A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens","source_id_and_acronym":"NCT02354586 - QUADRA","lead_sponsor":"Tesaro, Inc.","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA wild-type","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Completed","enrollment":" Enrollment 463","initiation":"Initiation: 03/23/2015","start_date":" 03/23/2015","primary_txt":" Primary completion: 02/28/2018","primary_completion_date":" 02/28/2018","study_txt":" Completion: 08/23/2021","study_completion_date":" 08/23/2021","last_update_posted":"2022-09-15"},{"id":"f7f988e5-3f12-4ed0-9eb8-bf487d893b48","acronym":"","url":"https://clinicaltrials.gov/study/NCT05440578","created_at":"2022-07-01T21:55:20.240Z","updated_at":"2024-07-02T16:36:07.901Z","phase":"","brief_title":"First-line Olaparib Combined With Bevacizumab Maintenance Therapy","source_id_and_acronym":"NCT05440578","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA wild-type • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA wild-type • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-07-01"},{"id":"08818835-fce5-4677-ad37-b0c9c5db4e23","acronym":"NPC-PAPRi 1.0","url":"https://clinicaltrials.gov/study/NCT04978012","created_at":"2021-07-27T15:52:48.629Z","updated_at":"2024-07-02T16:36:09.257Z","phase":"Phase 2","brief_title":"Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy","source_id_and_acronym":"NCT04978012 - NPC-PAPRi 1.0","lead_sponsor":"Fudan University","biomarkers":" PD-L1 • HRD","pipe":" | ","alterations":" HRD • BRCA wild-type","tags":["PD-L1 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiRuiYi (fluzoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 07/25/2021","start_date":" 07/25/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-06-07"},{"id":"438025c4-dfde-4a0d-952b-a87ea049c081","acronym":"PALB2-PARPi-01","url":"https://clinicaltrials.gov/study/NCT05232006","created_at":"2022-02-09T16:52:46.182Z","updated_at":"2024-07-02T16:36:15.918Z","phase":"Phase 2","brief_title":"PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers","source_id_and_acronym":"NCT05232006 - PALB2-PARPi-01","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • PALB2 mutation • BRCA wild-type","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • PALB2 mutation • BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 05/01/2030","study_completion_date":" 05/01/2030","last_update_posted":"2022-03-08"},{"id":"79829112-6f14-44d7-8fba-307f343222c4","acronym":"POLO","url":"https://clinicaltrials.gov/study/NCT05187208","created_at":"2022-01-11T15:56:12.250Z","updated_at":"2025-02-25T15:00:11.656Z","phase":"Phase 4","brief_title":"PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer","source_id_and_acronym":"NCT05187208 - POLO","lead_sponsor":"Seoul National University Hospital","biomarkers":" BRCA1 • BRCA2 • HRD","pipe":" | ","alterations":" HRD • BRCA wild-type","tags":["BRCA1 • BRCA2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-01-26"},{"id":"c181df35-21ad-4747-97be-77dd2430446d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05153603","created_at":"2021-12-10T23:53:32.746Z","updated_at":"2024-07-02T16:36:19.611Z","phase":"","brief_title":"Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting","source_id_and_acronym":"NCT05153603","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA wild-type • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA wild-type • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2021-12-10"},{"id":"2a67dca9-672c-44cc-ba63-72dc0d4ee9dd","acronym":"HOPEII","url":"https://clinicaltrials.gov/study/NCT05069818","created_at":"2021-10-06T12:54:04.965Z","updated_at":"2024-07-02T16:36:23.434Z","phase":"","brief_title":"Variance of HRD From Paired Ovarian Cancer","source_id_and_acronym":"NCT05069818 - HOPEII","lead_sponsor":"Xiaoxiang Chen","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD • BRCA wild-type • HRD + BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD • BRCA wild-type • HRD + BRCA1 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2021-10-06"},{"id":"87623a65-44d1-4a3c-a398-d7b357cf1a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT04655183","created_at":"2021-01-19T20:41:26.110Z","updated_at":"2025-02-25T16:10:52.282Z","phase":"Phase 2","brief_title":"Study of M4344 in Combination With Niraparib","source_id_and_acronym":"NCT04655183","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" HER-2 • BRCA1 • BRCA2 • HRD • BRCA","pipe":" | ","alterations":" EGFR mutation • HER-2 negative • BRCA wild-type • BRCA mutation","tags":["HER-2 • BRCA1 • BRCA2 • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 negative • BRCA wild-type • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • gartisertib (M4344)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2021-06-30"},{"id":"a80b269a-d9c8-4c72-8e65-f8b89fbe8a16","acronym":"","url":"https://clinicaltrials.gov/study/NCT03101280","created_at":"2021-01-18T15:17:15.624Z","updated_at":"2024-07-02T16:36:39.774Z","phase":"Phase 1","brief_title":"A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer","source_id_and_acronym":"NCT03101280","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA wild-type • BRCA mutation • PGR negative","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA wild-type • BRCA mutation • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Rubraca (rucaparib)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 04/27/2017","start_date":" 04/27/2017","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 08/11/2020","study_completion_date":" 08/11/2020","last_update_posted":"2020-10-22"},{"id":"03fb80ab-7f00-4137-a737-9413c4e6219b","acronym":"BREAKOUT","url":"https://clinicaltrials.gov/study/NCT03078036","created_at":"2021-01-18T15:09:51.222Z","updated_at":"2024-07-02T16:36:44.901Z","phase":"","brief_title":"International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study","source_id_and_acronym":"NCT03078036 - BREAKOUT","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA wild-type • BRCA mutation","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA wild-type • BRCA mutation"],"overall_status":"Completed","enrollment":" Enrollment 873","initiation":"Initiation: 03/13/2017","start_date":" 03/13/2017","primary_txt":" Primary completion: 05/20/2019","primary_completion_date":" 05/20/2019","study_txt":" Completion: 05/20/2019","study_completion_date":" 05/20/2019","last_update_posted":"2020-05-20"},{"id":"3c90f7b1-0c35-4491-9663-bd8394693c86","acronym":"MS201923_0001","url":"https://clinicaltrials.gov/study/NCT02157792","created_at":"2021-01-18T10:02:17.956Z","updated_at":"2025-02-25T16:13:53.639Z","phase":"Phase 1","brief_title":"M6620 First in Human Study","source_id_and_acronym":"NCT02157792 - MS201923_0001","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" HER-2 negative • BRCA wild-type","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • etoposide IV • irinotecan • berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 12/10/2012","start_date":" 12/10/2012","primary_txt":" Primary completion: 03/11/2020","primary_completion_date":" 03/11/2020","study_txt":" Completion: 03/11/2020","study_completion_date":" 03/11/2020","last_update_posted":"2020-04-01"}]